Comparing Henry Schein (HSIC) and TERUMO Corp/ADR (TRUMY)

Henry Schein (NASDAQ:HSIC) and TERUMO Corp/ADR (OTCMKTS:TRUMY) are both large-cap medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, profitability, earnings, valuation, analyst recommendations, risk and institutional ownership.


This table compares Henry Schein and TERUMO Corp/ADR’s net margins, return on equity and return on assets.

Net Margins Return on Equity Return on Assets
Henry Schein 3.00% 20.40% 7.71%
TERUMO Corp/ADR 15.73% 16.91% 8.71%

Analyst Ratings

This is a summary of current recommendations and price targets for Henry Schein and TERUMO Corp/ADR, as reported by MarketBeat.

Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Henry Schein 2 8 8 0 2.33
TERUMO Corp/ADR 0 0 0 0 N/A

Henry Schein currently has a consensus target price of $83.56, suggesting a potential downside of 2.91%. Given Henry Schein’s higher probable upside, research analysts clearly believe Henry Schein is more favorable than TERUMO Corp/ADR.

Valuation and Earnings

This table compares Henry Schein and TERUMO Corp/ADR’s gross revenue, earnings per share (EPS) and valuation.

Gross Revenue Price/Sales Ratio Net Income Earnings Per Share Price/Earnings Ratio
Henry Schein $12.46 billion 1.05 $406.29 million $3.60 23.91
TERUMO Corp/ADR $5.31 billion 3.93 $821.65 million $2.19 25.10

TERUMO Corp/ADR has lower revenue, but higher earnings than Henry Schein. Henry Schein is trading at a lower price-to-earnings ratio than TERUMO Corp/ADR, indicating that it is currently the more affordable of the two stocks.

Risk and Volatility

Henry Schein has a beta of 0.87, indicating that its stock price is 13% less volatile than the S&P 500. Comparatively, TERUMO Corp/ADR has a beta of 0.35, indicating that its stock price is 65% less volatile than the S&P 500.


TERUMO Corp/ADR pays an annual dividend of $0.21 per share and has a dividend yield of 0.4%. Henry Schein does not pay a dividend. TERUMO Corp/ADR pays out 9.6% of its earnings in the form of a dividend.


Henry Schein beats TERUMO Corp/ADR on 7 of the 13 factors compared between the two stocks.

Henry Schein Company Profile

Henry Schein, Inc. provides health care products and services to dental practitioners and laboratories, animal health clinics, physician practices, government, institutional health care clinics, and other alternate care clinics worldwide. It operates through two segments, Health Care Distribution, and Technology and Value-Added Services. The Health Care Distribution segment offers dental products, including infection-control products, handpieces, preventatives, impression materials, composites, anesthetics, teeth, dental implants, gypsum, acrylics, articulators, abrasives, dental chairs, delivery units and lights, X-ray supplies and equipment, and high-tech and digital restoration equipment, as well as equipment repair services. This segment also provides animal health products, such as branded and generic pharmaceuticals, surgical and consumable products and services, and equipment; and medical products comprising branded and generic pharmaceuticals, vaccines, surgical products, diagnostic tests, infection-control products, X-ray products, equipment, and vitamins. The Technology and Value-Added Services segment offers software, technology, and other value-added services that include practice management software systems for dental and medical practitioners, and animal health clinics. This segment also provides value-added practice solutions, which comprise financial services on a non-recourse basis, e-services, practice technology, network, and hardware services, as well as continuing education services for practitioners. The company was founded in 1932 and is headquartered in Melville, New York.

TERUMO Corp/ADR Company Profile

Terumo Corporation develops, manufactures, and distributes medical devices and services worldwide. It provides products for use in cardiothoracic surgery, interventional procedure, and medicine transfusion. The company offers vascular intervention devices, such as introducer sheathes, guide wires, angiographic catheters, and radial artery compression devices; therapeutic devices; and intravascular imaging systems, including optical frequency domain imaging and intravascular ultrasound systems. It also provides interventional oncology devices, such as micro balloon catheters, micro catheters and guide wires, and drug-elutable beads; cardiopulmonary bypass systems comprising oxygenators with integrated arterial filters, heart-lung machines, and devices for operating a centrifugal pumps for extracorporeal life support systems; and thoracic vascular and abdominal vascular grafts. In addition, the company offers infusion systems; closed anticancer drug infusion systems; blood glucose monitoring systems, digital blood pressure monitors, digital thermometers, pulse oximeters, walking intensity monitors, body composition monitors, and HR joint meter/monitors; sprayable adhesion barrier gels; analgesics; pharmaceuticals and nutritional supplements; and peritoneal dialysis devices and fluids. Further, it provides other consumer healthcare products, such as basal thermometers, fall prevention products, oral care products, and urine test strips; and blood bag systems with leukocyte reduction filters, automated blood collection and blood component processing systems, pathogen reduction technology systems, centrifugal apheresis systems, cell expansion systems, and autologous cell processing devices. The company was formerly known as Sekisen Ken-onki Corporation and changed its name to Terumo Corporation in October 1974. Terumo Corporation was founded in 1921 and is headquartered in Tokyo, Japan.

Receive News & Ratings for Henry Schein Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Henry Schein and related companies with's FREE daily email newsletter.

Leave a Reply